KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Common Equity: 2009-2024

Historic Common Equity for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $67.1 million.

  • Alnylam Pharmaceuticals' Common Equity rose 622.92% to $233.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.9 million, marking a year-over-year increase of 622.92%. This contributed to the annual value of $67.1 million for FY2024, which is 130.41% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Common Equity of $67.1 million as of FY2024, which was up 130.41% from -$220.6 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Common Equity registered a high of $1.0 billion during FY2020, and its lowest value of -$220.6 million during FY2023.
  • Its 3-year average for Common Equity is -$103.9 million, with a median of -$158.2 million in 2022.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Common Equity plummeted by 126.90% in 2022 and then surged by 130.41% in 2024.
  • Alnylam Pharmaceuticals' Common Equity (Yearly) stood at $1.0 billion in 2020, then tumbled by 42.12% to $588.2 million in 2021, then crashed by 126.90% to -$158.2 million in 2022, then plummeted by 39.45% to -$220.6 million in 2023, then skyrocketed by 130.41% to $67.1 million in 2024.